Harvia to boost sales in Japan by establishing a joint venture
Press release 7 March 2023
Harvia to boost sales in Japan by establishing a joint venture
Harvia Plc and Bergman Ltd have signed a letter of intent (LOI) on 7 March 2023 to create a joint venture in Japan with the mission to becoming a substantial local player in the attractive and growing Japanese sauna and spa market. Harvia will own 51% and Bergman 49% of the company.
The joint venture will focus on sales and marketing of Harvia’s sauna and spa offering on the Japanese market, and it is planned to be operational later this year.
Harvia signed an exclusive distribution agreement with Bergman Ltd, of Tokyo, Japan on 12 October 2021 to build awareness and demand for Harvia’s sauna and spa offering in Japan among both commercial and consumer customers. During the first 12 months of operations, Bergman increased presence with over 20 local representatives and opened a total of 15 showrooms in the market, with 7 more under way. In 2023, the plan is to increase the number of Harvia Sauna & Spa showrooms in Japan to a total of over 40.
“Our strategic partnership with Bergman has proven to be successful. We have been able to expand our presence in the Japanese sauna and spa market and sales have developed very favorably. The joint venture will further boost our activity in Japan and our aim is to become the number one sauna brand in Japan in the long run,” says Tapio Pajuharju, CEO of Harvia Plc.
“We are most pleased to deepen our co-operation with Harvia through the joint venture to be established. The sauna culture in Japan is enjoying a boom, and I am confident that our systematic activities with Harvia will help us to grow together to be the number one brand in both in residential and commercial sauna needs. Harvia already has a presence in major cities such as Tokyo, Osaka, Nagoya and Sapporo – and the presence is growing rapidly,” says Seiji Kasama, CEO of Bergman Ltd.
Bergman has more than 20 years of experience in marketing and selling branded European heating devices in Japan. The company has strong engineering and technical knowledge in design, installation, and after-sales services.
For more information, please contact:
Tapio Pajuharju, CEO, tel. +358 50 5774 200
Ari Vesterinen, CFO, tel. +358 40 5050 440
Harvia is one of the leading companies operating in the sauna and spa market globally, as measured by revenue. Harvia’s brands and product portfolio are well known in the market, and the company’s comprehensive product portfolio strives to meet the needs of the international sauna and spa market of both private and professional customers.
Harvia’s revenue totaled EUR 172.4 million in 2022. Harvia Group employs more than 600 professionals in Finland, China and Hong Kong, Romania, Austria, United States, Germany and Estonia. The company is headquartered in Muurame, Finland, adjacent to its largest sauna and sauna component manufacturing facility.
Read more: https://harviagroup.com
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Indkaldelse til ordinær generalforsamling i EAC Invest A/S - Selskabsmeddelelse nr. 2/202331.3.2023 10:58:37 CEST | pressemeddelelse
København, 31. marts 2023 Den ordinære generalforsamling i EAC Invest A/S vil blive afholdt fredag den 28. april 2023 kl. 11:00 i Asia House, Indiakaj 16, 2100 København Ø. Vedhæftet dagsorden med bilag. Med venlig hilsen, for EAC Invest A/S Bestyrelsen For yderligere information Kresten M. Valdal, CEO,Telefon: +45 82334044, e-mail investorinformation@eac.dk Vedhæftede filer EAC Invest AS - AGM 2023 IndkaldelseEAC Invest AS - AGM 2023 - Bilag 1 - Bestyrelseskandidater2023.02 Indkaldelse til ordinær generalforsamling i EAC Invest AS
Decisions of Innofactor Plc’s Annual General Meeting and the organizing meeting of the Board of Directors31.3.2023 10:20:00 CEST | Press release
Innofactor Plc Stock Exchange Release March 31, 2023, at 11.20 Finnish time Adopting the accounts and the group's financial statement and granting the members of the Board of Directors and the Chief Executive Officer discharge from liability The Annual General Meeting (AGM) of Innofactor Plc held on March 31, 2023, resolved to adopt the accounts and the group's financial statement for the financial period that ended on December 31, 2022, and granted the members of the Board of Directors and the Chief Executive Officer discharge from liability for the financial period that ended on December 31, 2022. Deciding on the use of the profit shown on the balance sheet and the payment of dividend The AGM decided, in accordance with the proposal of the Board of Directors, that no dividend will be paid for the financial period of 2022. The AGM decided on a repayment of capital of EUR 0,06 per share to be paid. The repayment of capital shall be paid to shareholders who on the record date of the cap
AFARAK GROUP SE'S PUBLISHES FINANCIAL STATEMENTS 202231.3.2023 10:18:29 CEST | Press release
09:15 London, 11:15 Helsinki, 31 March 2023 - Afarak Group SE ("Afarak" or "the Company") (LSE: AFRK, OMX: AFAGR) Annual Financial Report AFARAK GROUP SE'S PUBLISHES FINANCIAL STATEMENTS 2022 Afarak Group announces that it has published today its Board of directors report, Financial Statement for the year 2022, the Auditor’s Report and the Corporate Governance Statement which is available from the Company's website www.afarak.com. Afarak publishes the Financial Statements in accordance with European Single Electronic Format (ESEF) reporting requirements with the XHTML format labelled with XBRL tags, which are available as zip file attached to this release. A copy of the Board of Directors report and the Financial Statements for the year 2022 has been submitted to the UK's National Storage Mechanism. Afarak will hold its 2023 Annual General Meeting in Helsinki on within the time stipulated in the Finnish Companies Act. Helsinki 31 March 2023 Guy Konsbruck CEO For additional information,
Agillic named a leader in The Cross-Channel Marketing Hubs Landscape, Q1 2023 report by Independent Research Firm31.3.2023 10:02:56 CEST | Press release
Press release, Copenhagen, 31 March 2023 Agillic’s Omnichannel Marketing Automation Platform has been named in Forrester’s ‘The Cross-Channel Marketing Hubs Landscape, Q1 2023’ report as a notable vendor among CCMH vendor options for B2C marketing. The Forrester report for Cross-Channel Marketing Hubs (CCMHs) allows B2C executives to understand the value they can expect from a CCMH vendor, learn how vendors differ, and select the right one based on size and market focus. In the report, Forrester defines CCMHs as ‘Enterprise marketing technology that supports customer data management, analytics, segmentation, and workflow tools for designing, executing, and measuring marketing engagement across digital and offline channels.’ The overview recognises that B2C marketers are shifting their CCMH investments from traditional campaigns to investing more in providing customers with personalized and meaningful interactions. Marketers can use Cross-Channel Marketing Hubs, according to Forrester,
Junshi Biosciences Announces 2022 Full Year Financial Results and Provides Corporate Updates31.3.2023 10:00:42 CEST | Press release
SHANGHAI, China, March 31, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced financial results for the 2022 full year and provided corporate updates. FINANCIAL HIGHLIGHTS Total revenue was approximately RMB 1,453 million during 2022. Sales revenue from TUOYI® (toripalimab) alone was approximately RMB 736 million, representing an increase of approximately 79% compared to 2021. With the increase in commercialization capability, as well as the approval and launch of two more significant indications for TUOYI® in 2022, the company’s sales in the domestic market are gradually entering a positive cycle. Total research and development (“R&D”) expenses were approximately RMB 2,384 million in 2022, representing an increase of approximately 15% compared to 2021. The increase in R&D expenses